Navigation Links
Boehringer Ingelheim's Jeff Huth Elected as National Pharmaceutical Council's Chairman of the Board
Date:11/8/2013

WASHINGTON, Nov. 8, 2013 /PRNewswire-USNewswire/ -- The National Pharmaceutical Council (NPC) today announced that Jeff Huth, Senior Vice President, Managed Markets, Boehringer Ingelheim Pharmaceuticals Inc. (BI), has been elected chairman of its Board of Directors for 2013-14. Mr. Huth has served on NPC's Board since 2009 and has previously held the positions of vice chair and treasurer.

(Photo:  http://photos.prnewswire.com/prnh/20131108/DC13524)

"Throughout his tenure on our board, Jeff has been dedicated to promoting NPC and its role as a leading health care policy research organization," said NPC President Dan Leonard. "We're looking forward to having Jeff play an even more active role in leading NPC's efforts on issues related to balancing the needs of patients with the population, the value of pharmaceuticals, and the use of real-world evidence."

Mr. Huth has more than 30 years of experience in the pharmaceutical industry, where he has served in a wide spectrum of roles ranging from pre-clinical development to marketing and sales management.  His career with Boehringer Ingelheim has included international assignments at BI's affiliate in the United Kingdom and at corporate headquarters in Germany. Upon returning to the U.S., he assumed responsibility for marketing and in 2009 moved to his current position, for which he is responsible for pricing and contracting, trade relations, health economics and leading field-based teams interacting with customers in the private and government payer channels. In the U.S., BI develops and markets therapies in the respiratory, cardiovascular, metabolic, anti-viral and oncology areas.

The NPC Board also elected Anne Whitaker, President, North America Pharmaceuticals, Sanofi, as Vice Chair; David Martin, Vice President, Managed Markets, Value & Access Group, Eisai Inc. as Treasurer; and Giovanni Caforio, MD, President, U.S. Pharmaceuticals, Bristol-Myers Squibb Company, and Steven Romano, MD, Senior Vice President, Head, Medicines Development Group, Pfizer Inc, to serve on the executive committee.

About the National Pharmaceutical Council
The National Pharmaceutical Council is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation. Founded in 1953 and supported by the nation's major research-based pharmaceutical companies, NPC focuses on research development, information dissemination, and education on the critical issues of evidence, innovation and the value of medicines for patients. For more information, visit www.npcnow.org and follow NPC on Twitter @npcnow. 


'/>"/>
SOURCE National Pharmaceutical Council
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Boehringer Ingelheims interferon-free hepatitis C treatment portfolio strengthened by promising interim Phase 2a data
2. Pivotal Phase 3 Data from Boehringer Ingelheim Hepatitis C Portfolio to be Presented at 64th Annual AASLD Meeting
3. Boehringer Ingelheim Pharmaceuticals, Inc. colabora con Univision Communications Inc. para lanzar una campaña integrada en español
4. Boehringer Ingelheim Pharmaceuticals, Inc. Collaborates With Univision Communications Inc. To Launch An Integrated Campaign In Spanish
5. Boehringer Ingelheims investigational volasertib receives FDA Breakthrough Therapy designation
6. Boehringer Ingelheim Expands Investigation of Interferon-free Hepatitis C Treatment Regimens to Reach More Patient Types through Presidio Pharmaceuticals Clinical Collaboration
7. Boehringer Ingelheim Pharmaceuticals, Inc. Statement on RE-ALIGN Data
8. Boehringer Ingelheim Announces Agreement to Study Real-World Use of Oral Anticoagulants
9. Boehringer Ingelheim Renews and Expands License to NextBio Research Platform
10. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies
11. Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... Calif. , March 29, 2017  Experts ... recognized remote monitoring devices like  Soberlink Systems  as ... The consensus paper, published in early 2017, concluded ... and valuable in managing patient recovery." ... the Journal of Addiction Medicine, detail a range ...
(Date:3/29/2017)... , March 29, 2017  Glenmark Pharmaceuticals, ... for GSP 301, an investigational fixed-dose combination of ... mcg) administered twice-daily as a nasal spray being ... These results are from a recently completed Phase ... GSP 301 combination therapy versus mometasone, olopatadine or ...
(Date:3/29/2017)... , Mar. 29, 2017 Research and ... Market 2017-2021" report to their offering. ... The global lifestyle drugs market to ... The report, Global Lifestyle Drugs Market 2017-2021, has been ... experts. The report covers the market landscape and its growth prospects ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... Dr. Angela Cotey, a noted general ... accepting new pediatric patients, with or without a referral. Dr. Cotey knows that ... orthodontic outcome and experience. When patients receive early treatment, they may achieve straight teeth ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... buildings (MOBs) and other outpatient facilities, and who are the most active developers? ... those questions, Revista and Healthcare Real Estate Insights (HREI) found that outpatient medical ...
(Date:3/29/2017)... ... , ... Curio Wellness , a premium medical cannabis brand and trusted ... management team with prominent executives from both inside and outside the cannabis industry. ... Ted Dumbauld , who has more than twenty years of business leadership and investment ...
(Date:3/29/2017)... ... March 29, 2017 , ... HealthCareMandA.com will host an important webinar ... at 1:00 PM ET. A recording of the webinar will also be made available ... Home health and hospice companies are still popular targets for healthcare investors. This highly ...
(Date:3/29/2017)... ... 2017 , ... Immunotherapy has emerged as one of the most promising options ... be the next revolution in our fight against this complex disease. One of the ... checkpoint inhibitors such as PD-1 and PD-L1 inhibitors. , While a few single analyte ...
Breaking Medicine News(10 mins):